Sandra Weintraub1, Merilee Teylan2, Benjamin Rader2, Kwun C G Chan2, Mark Bollenbeck2, Walter A Kukull2, Christina Coventry2, Emily Rogalski2, Eileen Bigio2, M-Marsel Mesulam2. 1. From Mesulam Center for Cognitive Neurology and Alzheimer's Disease (S.W., B.R., C.C., E.R., E.B., M.-M.M.) and the Departments of Psychiatry and Behavioral Sciences (S.W., E.R.), Pathology (E.B.), and Neurology (M.-M.M.), Northwestern Feinberg School of Medicine, Chicago, IL; and Department of Epidemiology, National Alzheimer Coordinating Center (M.T., M.B., W.A.K.), and Department of Biostatistics (K.C.G.C.), University of Washington, Seattle. sweintraub@northwestern.edu. 2. From Mesulam Center for Cognitive Neurology and Alzheimer's Disease (S.W., B.R., C.C., E.R., E.B., M.-M.M.) and the Departments of Psychiatry and Behavioral Sciences (S.W., E.R.), Pathology (E.B.), and Neurology (M.-M.M.), Northwestern Feinberg School of Medicine, Chicago, IL; and Department of Epidemiology, National Alzheimer Coordinating Center (M.T., M.B., W.A.K.), and Department of Biostatistics (K.C.G.C.), University of Washington, Seattle.
Abstract
OBJECTIVE: To compare the proportion of APOE ε4 genotype carriers in aphasic vs amnestic variants of Alzheimer disease (AD). METHOD: The proportion of APOE ε4 carriers was compared among the following 3 groups: (1) 42 patients with primary progressive aphasia (PPA) and AD pathology (PPA/AD) enrolled in the Northwestern Alzheimer Disease Center Clinical Core; (2) 1,418 patients with autopsy-confirmed AD and amnestic dementia of the Alzheimer type (DAT/AD); and (3) 2,608 cognitively normal controls (NC). The latter 2 groups were compiled from the National Alzheimer Coordinating Center database. Logistic regression models analyzed the relationship between groups and APOE ε4 carrier status, adjusting for age at onset and sex as needed. RESULTS: Using NC as the reference and adjusting for sex and age, the DAT/AD group was 3.97 times more likely to be APOE ε4 carriers. Adjusting for sex and age at symptom onset, the DAT/AD group was 2.46 times as likely to be carriers compared to PPA/AD. There was no significant difference in the proportion of APOE ε4 carriers for PPA/AD compared to NC. PPA subtypes included 24 logopenic, 10 agrammatic nonfluent, and 8 either mixed (n = 5) or too severe (n = 3) to subtype. The proportion of carriers and noncarriers was similar for logopenic and agrammatic subtypes, both having fewer carriers. CONCLUSION: The proportion of APOE ε4 carriers was elevated in amnestic but not aphasic manifestations of AD. These results suggest that APOE ε4 is an anatomically selective risk factor that preferentially increases the vulnerability to AD pathology of memory-related medial temporal areas rather than language-related neocortices.
OBJECTIVE: To compare the proportion of APOE ε4 genotype carriers in aphasic vs amnestic variants of Alzheimer disease (AD). METHOD: The proportion of APOE ε4 carriers was compared among the following 3 groups: (1) 42 patients with primary progressive aphasia (PPA) and AD pathology (PPA/AD) enrolled in the Northwestern Alzheimer Disease Center Clinical Core; (2) 1,418 patients with autopsy-confirmed AD and amnestic dementia of the Alzheimer type (DAT/AD); and (3) 2,608 cognitively normal controls (NC). The latter 2 groups were compiled from the National Alzheimer Coordinating Center database. Logistic regression models analyzed the relationship between groups and APOE ε4 carrier status, adjusting for age at onset and sex as needed. RESULTS: Using NC as the reference and adjusting for sex and age, the DAT/AD group was 3.97 times more likely to be APOE ε4 carriers. Adjusting for sex and age at symptom onset, the DAT/AD group was 2.46 times as likely to be carriers compared to PPA/AD. There was no significant difference in the proportion of APOE ε4 carriers for PPA/AD compared to NC. PPA subtypes included 24 logopenic, 10 agrammatic nonfluent, and 8 either mixed (n = 5) or too severe (n = 3) to subtype. The proportion of carriers and noncarriers was similar for logopenic and agrammatic subtypes, both having fewer carriers. CONCLUSION: The proportion of APOE ε4 carriers was elevated in amnestic but not aphasic manifestations of AD. These results suggest that APOE ε4 is an anatomically selective risk factor that preferentially increases the vulnerability to AD pathology of memory-related medial temporal areas rather than language-related neocortices.
Authors: Britto P Nathan; Yanwen Jiang; Gene K Wong; Fei Shen; Gregory J Brewer; Robert G Struble Journal: Brain Res Date: 2002-02-22 Impact factor: 3.252
Authors: John C Morris; Sandra Weintraub; Helena C Chui; Jeffrey Cummings; Charles Decarli; Steven Ferris; Norman L Foster; Douglas Galasko; Neill Graff-Radford; Elaine R Peskind; Duane Beekly; Erin M Ramos; Walter A Kukull Journal: Alzheimer Dis Assoc Disord Date: 2006 Oct-Dec Impact factor: 2.703
Authors: E M Reiman; A Uecker; R J Caselli; S Lewis; D Bandy; M J de Leon; S De Santi; A Convit; D Osborne; A Weaver; S N Thibodeau Journal: Ann Neurol Date: 1998-08 Impact factor: 10.422
Authors: N Schuff; N Woerner; L Boreta; T Kornfield; L M Shaw; J Q Trojanowski; P M Thompson; C R Jack; M W Weiner Journal: Brain Date: 2009-02-27 Impact factor: 13.501
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Giovanni B Frisoni; Daniele Altomare; Dietmar Rudolf Thal; Federica Ribaldi; Rik van der Kant; Rik Ossenkoppele; Kaj Blennow; Jeffrey Cummings; Cornelia van Duijn; Peter M Nilsson; Pierre-Yves Dietrich; Philip Scheltens; Bruno Dubois Journal: Nat Rev Neurosci Date: 2021-11-23 Impact factor: 34.870
Authors: Molly Memel; Adam M Staffaroni; Yann Cobigo; Kaitlin B Casaletto; Corrina Fonseca; Brianne M Bettcher; Michael A Yassa; Fanny M Elahi; Amy Wolf; Howard J Rosen; Joel H Kramer Journal: Hippocampus Date: 2021-04-09 Impact factor: 3.753